The long-term benefits of the use of SGLT2 inhibitors should be studied in detail among the different HF subgroups and future investigations should include performance of SGLT2 inhibitors in those excluded from the current heart failure trials such as patients with amyloid cardiomyopathy, genetic hypertrophic or obstructive cardiomyopathy, primary uncorrected valvular disease or severe kidney disease. This evidence concerns the gene SLC5A2 and heart failure.